LinkedIn · Jun 2026
Arjun Murthy announced expansion into financing data, broadening the platform’s structured intelligence on capital raises and company activity.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Maven Bio is a Boston-based B2B AI platform for biopharma market intelligence. It helps pharma, biotech, consulting, and investment teams screen assets, benchmark competitors, monitor markets, and get cited answers grounded in primary sources and a curated life-sciences data library.
Primary product
Maven Bio’s AI-powered life sciences intelligence platform, centered on the Research Agent / AI Analyst and Smart Tables workflow
Founded
2023
Headquarters
24 Cambridge Street, Suite 7, Boston, MA 02129, United States
Team size
1-10
Work style
Hybrid
Industry
Business Intelligence Platforms
Sub-industry
Biopharma market intelligence / life sciences AI software
0 jobs at Maven Bio
Check back later for new openings
Offices
Business model
Leadership
CEO, Co-Founder
Co-Founder
Founding Applied AI Engineer
Founding Data Platform Engineer
Market Intelligence Lead
Market Intelligence Lead
Founding Applied AI Engineer
Founding SDR
Investors
Small, founder-led, high-ownership team with a builder mindset and a fast-moving, intense culture. Engineering roles are Boston-based four days a week, and the company explicitly emphasizes ownership, collaboration with founders, and offline weekends.
Work style
Hybrid
Compensation
Public job posts signal competitive salary, substantial equity, quarterly healthcare stipend, unlimited PTO, and high ownership. At least one commercial role was publicly posted with an $80K-$140K base plus commission and RSUs.
Benefits
Pricing
Free tier plus enterprise and usage-based pricing, with custom solutions for specialized workflows and data sources.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$400K-$500K ARR (estimated)
Estimated monthly visits
7.3K
Traffic estimate as of Aug 2024
LinkedIn · Jun 2026
Arjun Murthy announced expansion into financing data, broadening the platform’s structured intelligence on capital raises and company activity.
LinkedIn · Jun 2026
Arjun Murthy announced that Maven Bio added a new data layer for licensing, M&A, and collaboration deals across 30,000+ biopharma companies.
Maven Bio research · Jan 2026
Official Maven Bio research analyzing major 2025 pharma and biotech M&A, with emphasis on late-stage assets, platform technologies, and durable franchises.
LinkedIn · Apr 2025
Michael Brady announced the $3.1M seed round led by PagsGroup / Stephen Pagliuca’s family office and said the money would expand purpose-built AI agents for BioPharma strategy, BD, and investing teams.
LinkedIn · Oct 2024
Michael Brady announced the public launch out of beta, highlighting the AI-powered research experience, free tier, and cited workflows for competitive landscapes, tables, and instant answers.